- Home>
- Journal Watch
- >
- systemic sclerosis
Search for systemic sclerosis in all Journal Watch editions
Physician-authored summaries on the latest research on systemic sclerosis, editorials on systemic sclerosis, and perspectives on systemic sclerosis - drawn from the top medical journals.
Sort by:
Items 1 to 20 of 29 results - Relevance
- Date
You searched for: systemic sclerosis
-
Statins Might Benefit Digital Ulcerations and Raynaud Phenomenon
- October 17, 2008
- Jeffrey P. Callen, MD
- Dermatology
These relatively inexpensive agents hold promise for resolving digital ulcers in sclerosis-related Raynaud phenomenon.- Reviewing:
- Abou-Raya A et al., J Rheumatol 2008 Sep; 35:1801.
-
Audiovestibular Manifestations of Limited Systemic Sclerosis
- July 22, 2008
- Robert W. Baloh, MD
- Neurology
In a series of patients with lSSc, audiovestibular findings were most consistent with labyrinthine, rather than nerve, involvement.- Reviewing:
- Amor-Dorado JC et al., Medicine (Baltimore) 2008 May; 87:131.
-
A SNP in Systemic Sclerosis
- November 2, 2007
- Hensin Tsao, MD, PhD
- Dermatology
A polymorphism in the gene that expresses connective-tissue growth factor is involved in the risk for scleroderma.- Reviewing:
- Fonseca C et al., N Engl J Med 2007 Sep 20; 357:1210.
-
Bosentan -- A New Oral Therapy for Severe Raynaud Phenomenon
- January 18, 2005
- Jeffrey P. Callen, MD
- Dermatology
An endothelin antagonist that blocks vasoconstriction looks promising.- Reviewing:
- Korn JH et al., Arthritis Rheum 2004 Dec; 50:3985-93. Ramos-Casals M et al., Rheumatology (Oxford) 2004 Nov; 43:1454-6.
-
Low-Dose UVA1 Reduces Dermal Collagen in Systemic Sclerosis
- June 30, 2004
- James Ferguson, MD, FRCP
- Dermatology
Progressive systemic sclerosis (PSS) is a multisystem disease characterized by the presence of specific autoantibodies, altered immune activation, and massive collagen deposition in skin and . . .- Reviewing:
- Kreuter A et al., J Am Acad Dermatol 2004 May; 50:740-7.
-
Are Calcium-Channel Blockers Really Effective for Raynaud's in Systemic Sclerosis?
- October 24, 2001
- JP Callen
- Dermatology
Nifedipine and other calcium-channel blockers have been used for primary and secondary Raynaud's phenomenon (RP), but how well have these agents been studied? Using the . . .- Reviewing:
- Thompson AE et al., Arthritis Rheum 2001 Aug; 44:
1841 1847 .
-
Systemic Sclerosis and Gastric Function
- February 13, 2001
- DJ Bjorkman
- Gastroenterology
Systemic sclerosis is an inflammatory disorder that affects the smooth muscle of the gastrointestinal tract; its effects on esophageal function are well described. To study . . .- Reviewing:
- Marie I et al., Am J Gastroenterol 2001 Jan; 96:
77 83 .
-
Moderate-Dose UVA-1 for Systemic Sclerosis
- December 11, 2000
- J Ferguson
- Dermatology
The skin thickening, flexion contractures, and bony prominence ulceration in systemic sclerosis are largely untreatable. The ability of UVA-1 (320-400 nm) to induce helper-T-cell apoptosis . . .- Reviewing:
- Morita A et al., J Am Acad Dermatol 2000 Nov; 43:
670 674 .
-
POSSIBLE ASSOCIATION BETWEEN SYSTEMIC SCLEROSIS AND SILICONE IMPLANTS.
- September 19, 1989
- ASB
- General Medicine
This intriguing report suggests a possible connection between augmentation mammoplasty with silicone-gel implants and systemic sclerosis (scleroderma). The authors encountered four patients in whom systemic . . .- Reviewing:
- Varga J et al., Ann Intern Med 1989 Sep 1; 111:
377 383 .
-
Is Localized Scleroderma in Childhood a Systemic Disease?
- September 27, 2005
- Jeffrey P. Callen, MD
- Dermatology
Scleroderma is rare in children. It has been subclassified as localized scleroderma and systemic scleroderma. Localized scleroderma has been further divided into plaque morphea, generalized . . .- Reviewing:
- Zulian F et al., Arthritis Rheum 2005 Sep; 52:2873-81.
-
Regressing Systemic Sclerosis?
- July 10, 2000
- NH Shear
- Dermatology
Systemic sclerosis (scleroderma) is predominately characterized by fibrosis of tissue, including skin and the intima of small arteries. The pathogenesis is unknown, and therapy has . . .- Reviewing:
- Seibold JR et al., Ann Intern Med 2000 Jun 6; 132:
871 879 .
-
Predicting Prognosis for Scleroderma Patients
- April 30, 2002
- Jeffrey P. Callen, MD
- Dermatology
Scleroderma is a connective tissue disease characterized by variable degrees of fibrosis affecting the skin and viscera. Its course is variable, and its prognosis may . . .- Reviewing:
- Ferri C et al., Medicine (Baltimore) 2002 Mar; 81:139-53. Scussel-Lonzetti L et al., Medicine (Baltimore) 2002 Mar; 81:154-67.
-
Dermatomyositis Patients with the MDA-5 Antibody Have Increased Pulmonary Disease and Skin Ulcerations
- October 19, 2012
- Jeffrey P. Callen, MD
- Dermatology
But our author prefers to test all DM patients for interstitial lung disease.- Reviewing:
- Cao H et al., Arthritis Care Res 2012 Oct; 64:1602.
-
UVA1 Is Often A1! Free
- April 27, 2012
- Mark V. Dahl, MD
- Dermatology
After reviewing the evidence, a workshop group discusses the effectiveness, safety, and costs of UVA1 phototherapy.- Reviewing:
- Kerr AC et al., Clin Exp Dermatol 2012 Apr; 37:219.
-
Another Myositis-Specific Antibody: Is It Linked to Malignancy?
- April 6, 2012
- Jeffrey P. Callen, MD
- Dermatology
Patients with an idiopathic inflammatory myopathy and the anti-NXP2 autoantibody may have increased risk for an internal malignancy.- Reviewing:
- Ichimura Y et al., Ann Rheum Dis 2012 Jan 17;:
-
A Marker for Autoimmune Pancreatitis?
- November 25, 2009
- Stuart Sherman, MD
- Gastroenterology
A potential serologic marker did not completely differentiate AIP and pancreatic cancer.- Reviewing:
- Frulloni L et al., N Engl J Med 2009 Nov 26; 361:2135.
-
Antihistone Antibodies: Not as Useful as Hoped
- May 25, 2004
- Jeffrey P. Callen, MD
- Dermatology
Although they are classically associated with drug-induced lupus erythematosus (LE), antihistone antibodies (AHAs) are often present in patients with other autoimmune disease. To determine the . . .- Reviewing:
- Zirwas MJ et al., Arch Dermatol 2004 Apr; 140:494-5.
-
Peripheral Nerve Manifestations of Connective Tissue Diseases
- March 28, 2001
- KK Nakano
- Neurology
Connective tissue (CT) diseases, such as rheumatoid arthritis, Sjögren's syndrome, systemic lupus erythematosus, systemic sclerosis, and vasculitis, may cause disorders of the peripheral nervous system . . .- Reviewing:
- Rosenbaum R., Muscle Nerve 2001 Feb; 24:
154 169 .
-
Localized Scleroderma Treated with Topical PUVA Cream
- January 12, 2001
- J Ferguson
- Dermatology
Although not usually as incapacitating as systemic sclerosis, localized scleroderma (LS) can significantly restrict a patient's mobility and quality of life. Current treatment options are . . .- Reviewing:
- Grundmann-Kollmann M et al., J Am Acad Dermatol 2000 Oct; 43:
675 678 .
-
Should Patients Using Minocycline Be Tested for Antineutrophilic Cytoplasmic Antibodies?
- December 22, 2000
- JP Callen
- Dermatology
Minocycline has been linked to the development of lupus-like syndromes and, occasionally, vasculitis. These syndromes occur rarely, and it is not known whether testing prior . . .- Reviewing:
- Choi HK et al., Arthritis Rheum 2000 Nov; 43:
2488 2492 .
Sort by:
Items 1 to 20 of 29 results - Relevance
- Date
